McKesson Corp. Stock
McKesson Corp. Stock
The McKesson Corp. stock is trending slightly upwards today, with an increase of €5.20 (1.000%) compared to yesterday's price.
With 23 Buy predictions and not a single Sell prediction McKesson Corp. is an absolute favorite of our community.
With a target price of 551 € there is a slightly positive potential of 5.07% for McKesson Corp. compared to the current price of 524.4 €.
Pros and Cons of McKesson Corp. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of McKesson Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
McKesson Corp. | 1.000% | 1.471% | 6.068% | 43.671% | 26.667% | 234.545% | 379.780% |
Cardinal Health Inc. | -0.660% | 2.994% | -4.707% | 18.034% | 1.667% | 98.827% | 142.706% |
CVS Health Corp. | 5.890% | 7.306% | 6.826% | -15.958% | -23.325% | -22.019% | 16.847% |
AmerisourceBergen Corp. | 2.500% | 3.444% | -0.406% | 28.083% | 13.476% | 120.899% | 197.746% |
Comments
McKesson Co. (NYSE: MCK) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $547.00 to $545.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MCK provided by MarketBeat
McKesson Co. (NYSE: MCK) had its price target raised by analysts at Barclays PLC from $571.00 to $596.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for MCK provided by MarketBeat
McKesson Co. (NYSE: MCK) had its price target raised by analysts at TD Cowen from $563.00 to $652.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MCK provided by MarketBeat
News
McKesson (MCK) Q4 2024 Earnings Call Transcript
McKesson (MCK) Q3 2024 Earnings Call Transcript
This 1 Surprising New Tailwind Is Lifting These 2 Evergreen Stocks
Bigtime medical distributors like McKesson (NYSE: MCK) and Cencora (NYSE: COR) make money by moving drugs and supplies to clinics and pharmacies worldwide. While investors usually look to such